237 results about "Viral Activity" patented technology

A method and system that reduces the length of time required to complete antivirus scans. An enhanced journal file system (JFS) includes an antivirus utility function, which utilizes a low level log of the JFS to store a history of transactions that occur since a previous scan operation. The log is immune from normal purge operations by the JFS and cannot be circumvented without driver level access. Thus, a virus that changes the timestamp on the file or otherwise attempts to hide its viral activity does not affect the log. When the antivirus scanning utility initiates an antivirus scan of the system, the antivirus scanning utility obtains the history since the last scan from the persistent log. The antivirus scanning utility “replays” the log and carries out the antivirus scan on all files, directories, etc. associated with any transactions that occurred since the last scan.

A method of treating, preventing or ameliorating one or more symptoms of hepatitis C, or inhibiting cathepsin activity, in a subject is provided, in which at least one compound (e.g., a HCV protease inhibitor) is administered in one or more discrete dosages over a twenty-four hour time interval in an asymmetric pattern as to dosage amount and/or timing of dosage, wherein the at least one compound is selected from the group consisting of compounds of Formulae I-XXVI, described herein. Methods of modulating the activity of hepatitis C virus protease in a subject are also provided. Asymmetric dosing as to amount of dose and/or timing of dose permits adjustment of dosing to accommodate variations in drug metabolism and/or viral activity caused by viral cell division or a patient's circadian rhythms, thus delivering the maximum amount of dose at the time or times it is most effective.

A method of imparting a rapid and a persistent antiviral activity against viral-mediated diseases is disclosed. The method includes applying an antimicrobial compositions containing (a) a disinfecting alcohol, (b) an organic acid, and (c) water, and having a pH of about 5 or less, to at least one of the nose, nasal passages, and surrounding facial areas of skin of an individual.

Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral infections.

There are provided multimeric fusion proteins exhibiting anti-viral activity. The fusion proteins comprise the HR2 region of the ectodomain of the human immunodeficiency virus gp41 protein which is fused to a multimerisation domain peptide such as a trimerisation domain derived from tetranectin. The multimerised fusion proteins may be used as HIV fusion inhibitors in the treatment of AIDS.

The present invention provides: an antibacterial/antiviral composition which has excellent antibacterial/antiviral activity under visible light irradiation; an antibacterial/antiviral agent; a photocatalyst; and a bacteriairus inactivation method. An antibacterial/antiviral composition according to the present invention contains titanium oxide on which both a divalent copper compound and a silver compound are loaded. An antibacterial/antiviral agent according to the present invention and a photocatalyst according to the present invention contain an antibacterial/antiviral composition according to the present invention. A bacteriairus inactivation method according to the present invention inactivates bacteria and a virus with use of an antibacterial/antiviral composition according to the present invention, an antibacterial/antiviral agent according to the present invention or a photocatalyst according to the present invention.

A composition comprising of polyphenols, an ascorbic compound, lysine, and proline, have been found to retard viral activity. As such, methods of treating viral infection, and methods of retarding viral activity are provided herein.

Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.

The present invention discloses an organic ionic compound having anti-viral activity and the method for antagonizing virus in vitro by putting the compounds in contact with the virus.

The invention discloses an application of artemisinin and derivatives thereof in preparation of medicaments for treating hepatitis C viruses (HCV). The medicaments which almost do not have toxic concentration are used for anti-virus test; and by detecting the influence of the artemisinin and the derivatives thereof such as dicyanogen artemisinin, artemether and artesunate on HCV replication, the artemisinin and the derivatives thereof serving as small molecular compounds have remarkable viral activity resistance and are dose-dependent. The artemisinin and the derivatives thereof which have already been used for clinical antimalarials have low toxic or side effect on a human body. The artemisinin and the derivatives thereof which almost do not have toxicity can inhibit about 90 percent of HCV replication, and are efficient and low-toxic anti-HCV compounds. The compounds have a broad prospect for developing anti-HCV medicaments.

The invention provides alpha-pyrone compounds having antiviral activity and their application in resisting influenza viruses H1N1 and H3N2. The invention also discloses a preparation method of the alpha-pyrone compounds having antiviral activity, comprising: (1) acquiring a fermented material having rich pyrone compounds through microbial fermentation culture, wherein a recombinant vector used inthe microbial fermentation culture carries polyketide synthase having a nucleotide sequence of KU534995.1; (2) separating and purifying the fermented material of step (1) to obtain the alpha-pyrone compounds. Compared with existing drugs, the pyrone compounds have good anti-H2N1 and anti-H3N2 activity and are substantially nontoxic to normal cells; compared with existing drugs, the alpha-pyrone compounds have natural advantages, including good activity and toxic and side effects reduced as far as possible, and also have a promising application prospect and huge market.

The invention relates to human alpha-defensin 5 (HD5) antiviral active mutant polypeptide and preparation method and application. The 21th glutamic acid in HD5 of the amino acid sequence of the mutant polypeptide can be replaced into arginine (E21R). The preparation method of the mutant polypeptide has two preparation methods, namely a solid-phase chemical synthesis method and a gene engineering preparation method. The HD5 mutant polypeptide of the invention has efficient antiviral activity under the conditions that serum exits or absents, and compared with parent HD5 polypeptide, the antiviral function of the invention is obviously improved. The HD5 mutant polypeptide of the invention is used for preventing viral infection, such as HSV, HPV, HIV and the like.

The invention discloses an ophthalmic medicament and a preparation method thereof. The ophthalmic medicament comprises a phyllanthus emblica extract and water for injection. The ophthalmic medicamentcan provide a protective effect on viruses capable of being infected by eyes in a targeted manner; experimental research shows that the ophthalmic medicament has relatively efficient broad-spectrum antiviral activity, particularly has a remarkable treatment effect on new coronavirus and influenza virus, can effectively inhibit infection and propagation of the viruses, and has good prevention and control significance on propagation of diseases caused by virus infection on human bodies. The main effective components of the ophthalmic medicament are from natural plants, so that the ophthalmic medicament has the advantages of naturalness, safety, mild drug effect and the like, and the preparation method is simple, low in cost and very good in application prospect.

Peptides having activity of inhibiting infections of respiratory viruses and use of the same are disclosed. The peptides can be synthesized by chemical or genetic engineering methods, and they have functional domain capable of binding to surface glycoprotein of respiratory viruses and activity of inhibiting infections of respiratory viruses. The peptides are useful for blocking infections of respiratory viruses in target cells, for prevention/treatment of said infections, and for development of new prophylactic/therapeutic medicaments against respiratory viruses. Also disclosed are a kit for screening peptide capable of inhibiting said infections and the screening method. The invention also discloses the mechanism of the peptides in inhibition of said infections, which provides theory support for developing new prophylactic/therapeutic agents with broad-spectrum antiviral activities.

Viruses, and particularly RNA viruses, have high mutation rates. Hence, antiviral agents that have been developed to date targeting protease or reverse transcriptase of viruses have quickly lost their effectiveness and resistant viruses have emerged. Also, in recent years, viral diseases caused by various new viruses such as SARS, avian influenza, and the hepatitis C have become social menaces. Therefore, the development of a novel antiviral agent that can cope with a virus resistant to an existing drug or a new virus and has a wide range of applications has been demanded. The present invention provides a novel anti-RNA viral agent and a method for use thereof. The present invention further provides an anti-RNA viral agent that is also effective against a new virus or a drug-resistant virus, and a method for use thereof.

The invention discloses a series of erythromycin A ketolide antibiotic derivatives containing quinoline substituent group, represented by a formula I. The invention also provides preparation methods and applications of the derivatives, and side-chain intermediates of the compounds and synthesis methods thereof. The key point of the invention is that the compounds represented by the formula I have the efficacy of broad-spectrum antibiotics, and have outstanding antibacterial activity and anti-resistance activity in inhibiting Gram-positive bacteria and Gram-negative bacteria. The compounds provided by the invention can be used as broad-spectrum antibiotics, and also have antibacterial and antiviral activities in inhibiting Gram-positive bacteria and Gram-negative bacteria.

The invention provides an antiviral water-based matrix emulsion composition and an antiviral coating containing the same. The emulsion composition is composed of an inorganic metal nanocomposite dispersion liquid with photocatalytic antiviral activity, a water-based high-molecular polymer emulsion containing a high-content quaternary phosphonium salt unit, and an optional polyvinyl alcohol auxiliary agent. The water-based matrix emulsion or the coating thereof can be used for surface coating treatment of textile articles, plastic products, glass products, leather, wooden products and other objects, so that the virus activity on the surfaces of the objects is reduced or inactivated in a short time, and the effects of inhibiting viruses and blocking propagation are achieved.